Last reviewed · How we verify
NCT06152666
Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
trial testing None - qualitative interviews in Bladder Cancer in 15 participants. Status unknown.
1 April 2024
Quick facts
| Lead sponsor | Royal Devon and Exeter NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 December 2023 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- None - qualitative interviews
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
- Bladder Outlet Obstruction — all drugs for Bladder Outlet Obstruction →
- Urolithiasis — all drugs for Urolithiasis →
Sponsor
Royal Devon and Exeter NHS Foundation Trust
Who can join
Eligibility, any sex, with Bladder Cancer or Bladder Outlet Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A qualitative research study conducted in hospitals across England, in which staff members will be interviewed. We will interview staff who are directly or indirectly involved in delivering care for patients undergoing the operations of interest; namely bladder tumour resection, prostate resection or enucleation, and ureteroscopy for upper urinary tract stones. We hope to find out the reasons why some hospitals can perform day-case surgery with very high rates, and why others do not. We also hope to find out about any unexpected outcomes observed when performing day-case surgery for the operations of interest. Staff working in a range of different hospitals from across England with varying day-case rates will be interviewed. Hospitals in large city and more rural areas will be assessed. Interviews are anticipated to take place over a six month period. The study will end when "saturation" is achieved, whereby no new themes are identified through interviews. Saturation will be sought for each individual operation of interest.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06152666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of None - qualitative interviews
Trials testing the same drug.
- NCT06152679 — Day-case Endourology; Patient Experience · unknown
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Royal Devon and Exeter NHS Foundation Trust trials
Trials by the same sponsor.
- NCT06685874 — Interstitial Lung Disease Exacerbations Study · active not recruiting
- NCT06903780 — Experience of Biologic Treatments for Severe Asthma: a Survey · recruiting
- NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting
- NCT06523452 — Laser Speckle Imaging During Breast Reconstruction · NA · recruiting
- NCT06099691 — Outcomes That Matter and Questionnaires for Older People With Frailty · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06152666 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Devon and Exeter NHS Foundation Trust
- Last refreshed: 1 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06152666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing